Beta Drugs Ltd. · NSE:BETA
Beta Drugs — Investor Presentation (November 2023)
24 slides from Beta Drugs's investor presentation, Nov 8, 2023
Slide 1: Investor Presentation H1 '24
Investor Presentation H1 ‘24
Slide 2: Disclaimer
Disclaimer • This corporate presentation has been prepared by Beta Drugs Limited (the “Company”) solely for information purposes without regard to any specific objectives, financial situations or informational needs of any particular person. • This presentation should not be construed as legal, tax,
Slide 3: Quick overview
Quick overview 43.7% Revenue CAGR of branded formulations Will be the youngest 1 Only Indian company Company to cross INR (FY21-23) Market focused exclusively on 1,000 mn in oncology position Fastest growing domestic oncology branded formulations oncology formulations revenue company INR 539 mn INR
Slide 4: H1'24 Highlights
H1’24 Highlights 1 Healthy business growth across all verticals 2 Launch of 4 new brands 3 Improvement in financial performance 4 Develop 4 new API 5 Filed more than 30 dossiers in semi regulated and emerging markets
Slide 5: Healthy Growth Across All Segments in H1'24 (Y-O-Y)
Healthy Growth Across All Segments in H1’24(Y-O-Y) DOMESTIC OWN International API Business CDMO BRAND business 24 % growth 11.8 % growth 2 % growth 34.3% growth
Slide 6: Financial overview
Financial overview PERFORMANCE Growth FY’22 FY’23 H1’23 H1’24 over (Rs Cr) (Rs Cr) (Rs Cr) (Rs Cr) H1’23 Total revenue 183.84 227.11 112.38 141.26 25.7% EBITDA 43.51 53.88 27.13 33.39 23.1% EBITDA % 23.6% 23.7% 24.1% 23.6% PAT 24.83 30.72 15.83 19.87 25.5% PAT % 13.51% 13.53% 14.09% 14.07%
Slide 7: Financial Performance
Financial Performance --------------------------------------- 60.0 EBITDA 53.9 Debt to equity ratio 50.0 43.5 40.0 0.25 33.4 0.21 30.0 25.2 0.16 0.14 20.0 10.0 0.0 FY'21 FY'22 FY'23 H1'24 FY'21 FY'22 FY'23 H1'24 ----------------------------------------------------------------------------------------
Slide 8: Balance Sheet
Balance Sheet FY’22 FY’23 H1’23 H1’24 (Rs Cr) (Rs Cr) (Rs Cr) (Rs Cr) Share capital 9.61 9.61 9.61 9.61 Reserves 82.73 113.27 98.41 132.36 Borrowing (Long 16.58 16.04 15.62 15.42 term & short term) Other liabilities 48.93 59.5 51.58 79.87 Total liabilities 157.85 198.42 175.22 237.26 Fixed asset 54.
Slide 9: Company overview
Company overview ▪ Integrated oncology focused company with fast growing branded formulations business and having strong presence in formulation exports, CDMO and API ▪ Growing export business catering to LATAM, semi regulated and emerging markets like Southeast Asia, Africa, CIS/Russia ▪ Strong R&D
Slide 10: Key Competitive Strengths
Key Competitive Strengths Among top 10 players in cytotoxic market Will be the youngest Company to Among the few Indian cross INR 1,000 mn in oncology companies backward integrated branded formulations revenue for key APIs Among the few Indian companies Focus on novel delivery and backward integrate
Slide 11: Making Complex Oncology products Accessible to Indian cancer patients
Making Complex Oncology products Accessible to Indian cancer patients Building healthier world By providing affordable & With focus on R&D quality Oncology medicines With 2 formulations & 1 API state-of- 68 products 22 new products launched in last 4 the-art manufacturing facilities 118 SKUs years 1
Slide 12: Formulations and API Plant
Formulations and API Plant BETA DRUGS LTD. ADLEY FORMULATIONS PVT LTD. ADLEY LAB LTD. : API Plant Address: Address: Address: KHARUNI-LODHI MAJRA VILLAGE KOTLA,P.O. D-27 FOCAL POINT ROAD,VILL.NANDPUR,BADD BAROTIWALA,SOLAN DERABASSI SAS I-174101 DIST-SOLAN (HP) (HP)-174103 Nagar PUNJAB Facility for ma
Slide 13: Affordable Quality Medicine
Affordable Quality Medicine Leading brands
Slide 14: Focus on R&D
Focus on R&D New product development are pivotal to our growth
Slide 15: Focus on R&D
Focus on R&D 4 new brands launched in H2’24: Adstrom, Kylonib, Vicentra & Adcimab Working on NDDS (New Drug Delivery System). Received DCGI approval for Enzalutamide 160mg. Working on FFTLs to be launched in FY’24
Slide 16: Domestic Own Brand Business
Domestic Own Brand Business Domestic Own Brand Business Sales …with strong market position in each of the sub therapies 68 Targeted therapy1 Cytotoxics Supportive Hormonal therapy Market size (INR 41 mn) 12,461 9,121 3,861 3,495 34 Beta’s covered market (INR mn) 3,453 7,137 1,468 2,977 FY'23 H1'23 H
Slide 17: Leveraging our Strength for the Growth in Domestic Market
Leveraging our Strength for the Growth in Domestic Market Increasing our presence in tier 2 & tier 3 cities Our products are cost effective due NDDS formulations are giving backward integration. It is helping competitive edge to grow in us to get entry in more number of domestic market Govt & corpor
Slide 18: International Business
International Business Well positioned for growth in semi-regulated and emerging markets ▪ Received ANVISA and INVIMA approval recently LATAM 127 ▪ Key countries – Brazil, Venezuela, Colombia, Mexico, Chile and Peru Dossiers to be filed ▪ Expected to start commercialization in Brazil by FY26 ▪ Curre
Slide 19: International Business
International Business Global accreditations received by Beat through years 2016 2017 2018 2019 2020 2021 2022 2023 2024 DHA Nepal Tanzania INVIMA EUGMP Uganda Nigeria Cambodia Ethiopia WHO GMP ANVISA Kenya Sri Lanka Malawi Philippines Eurasia (Awaited) Plans to expand in regulated ANVISA and INVIMA
Slide 20: Strong In-House API Development
Strong In-House API Development
Slide 21: API Expansion Plan
API Expansion Plan • Foraying into the European market • In FY’25 planning to file 5 CEPs • Focus on export in the nonregulated, semi- regulated, and regulated market Geographical expansion Increase • Plant audit by major pharmaceutical presence in companies for Indian business domestic • Increasing
Slide 22: Our CDMO Partners
Our CDMO Partners ✓ Partnership with 50+ companies ✓ 20+ top pharma companies are associated with us since last 5 years Trusted ✓ One new dedicated injectable block added at Adley formulations plant Partners with 2 more lyophilizer (Production started) ✓ Capacity of lyophilized products has increase
Slide 23: Foraying into Cosmetic Dermatology
Foraying into Cosmetic Dermatology Total Market :~ 13700 Cr. Aesthetic Medical Market size: 3600Cr Market size: 10100Cr Fast growing market: 15% Y-O-Y growth 20% growth of the aesthetic market & 12 % growth of the medical Dermatology market First to launch product Product Acceptance Future Plan Sign
Slide 24: Thank You
THANK YOU Head office: SCO 184, Sector 5 Panchkula 134114 Haryana (India) Website: www.betadrugslimited.com Email: info@betadrugslimited.com